Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HR1405-01 for postoperative abdominal pain
CTR20254496Phase 3Completed
- Sponsor
- Nanjing Hairong Pharmaceutical Technology
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of HR1405-01 in postoperative pain (3 arms), sponsored by Nanjing Hairong Pharmaceutical Technology. Primary endpoint: Area under the pain intensity-time curve at rest from 0 to 24 hours (AUC0–24h). Started Dec 2025; status: completed.
02
Drugs
HR1405-01
03
Conditions
postoperative pain
Beyond the preview
Go deeper on CTR20254496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254496.